In addition to enhanced resolution, the uMR Jupiter 5T device reportedly addresses image uniformity and radiofrequency safety that have been previous challenges with ultra-high-field MRI.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the uMR Jupiter 5T system, the first ultra-high-field magnetic resonance imaging (MRI) system to gain clearance for full-body exams.
Equipped with an eight-channel whole-body multi-transmit system, the uMR Jupiter 5T system bolsters the clarity and detail of anatomical structures, according to United Imaging, the manufacturer of the device. The company said the 5T MRI system offers enhanced imaging capabilities for the heart, abdomen and pelvis that will facilitate improved diagnostic precision.
In addition to improved visualization of challenging anatomical regions, United Imaging noted that the device’s design and technology address previous issues associated with ultra-high-field MRI by ensuring radiofrequency safety and consistent imaging quality.
“We have always prioritized innovation that can make a broad clinical impact. Because it is aimed first and foremost at bringing ultra-high-field into greater clinical use, we believe (the uMR Jupiter 5T system) will have an exciting impact across our industry, and for clinical patients across the globe who have never had access to ultra-high-field in the past,” noted Jeffrey M. Bundy, Ph.D., the president and chief commercial officer of United Imaging in North America.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.